Ionis Pharmaceuticals Inc(IONS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:40 PM ET (Korea 10/28 05:40)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.47 | Insider Own | 1.97% | Shs Outstand | 165.6M | Perf Week | -3.17% |
| Market Cap | 7.31B | Forward P/E | - | EPS next Y | 41.7% | Insider Trans | -9.04% | Shs Float | 162.9M | Perf Month | -3.53% |
| Enterprise Value | 7.44B | PEG | - | EPS next Q | -1.22 | Inst Own | 107.64% | Short Float | 12.68% | Perf Quarter | -18.65% |
| Income | -0.56B | P/S | 8.36 | EPS this Y | -50.25% | Inst Trans | 4.28% | Short Ratio | 6.46 | Perf Half Y | -38.76% |
| Sales | 0.87B | P/B | 16.56 | EPS next 5Y | - | ROA | -18.89% | Short Interest | 20.65M | Perf YTD | -44.43% |
| Book/sh | 2.65 | P/C | 3.56 | EPS past 3/5Y | -7.82% 5.62% | ROE | -105.42% | 52W High | -49.32% ($86.74) | Perf Year | -39.77% |
| Cash/sh | 12.36 | P/FCF | - | Sales past 3/5Y | 17.12% 5.29% | ROIC | -21.59% | 52W Low | 4.47% ($42.08) | Perf 3Y | -0.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -98.12% | Gross Margin | 95.66% | Volatility(W/M) | 3.1% 3.35% | Perf 5Y | 47.47% |
| Dividend TTM | - | EV/Sales | 8.51 | Sales Y/Y TTM | -7.49% | Oper. Margin | -68.09% | ATR (14) | 1.67 | Perf 10Y | 71.12% |
| Dividend Ex-Date | - | Quick Ratio | 7.73 | EPS Q/Q | -202.29% | Profit Margin | -64.64% | RSI (14) | 44.22 | Recom | 1.46 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.89 | Sales Q/Q | -40.73% | SMA20 | 0.31% ($43.82) | Beta | 0.43 | Target Price | $84.14 |
| Payout | - | Debt/Eq | 4.98 | Earnings | 2026/7/29 | SMA50 | -11.99% ($49.95) | Rel Volume | 0.74 | Prev Close | $43.42 |
| Employees | 1402 | LT Debt/Eq | 4.95 | EPS/Sales Surpr. | 36.63% 41.73% | SMA200 | -34.7% ($67.32) | Avg Volume(3M) | 3.20M | Price | $43.96 |
| IPO | 1991/5/17 | Option/Short | Yes/Yes | Trades | 14246 | Volume | 2,376,843 | Change | 1.24% |
This U.S. biopharmaceutical company is a leading player in antisense drug development, creating treatments for rare and chronic diseases based on antisense technology that regulates protein production at the genetic level. The company is currently transitioning toward the commercialization of its own drug products.
Over the past 1 year, on the lower side
49% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
IONS has a sound balance sheet but weak earning power
Of every $100 in sales, $68.09 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -50.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $836. Peers typically go for $1,648.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +47.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 107.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
MEDX Horizon Kinetics Medical ETF 0.05% 
PBE Invesco Biotechnology & Genome ETF 0.02% 
PTH Invesco Dorsey Wright Healthcare Momentum ETF 0.02% 
FFOX FundX Future Fund Opportunities ETF 0.02% 
QMOM Alpha Architect U.S. Quantitative Momentum ETF 0.02% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares 49.3B 
JEPI JPMorgan Equity Premium Income ETF 45.8B 
JEPQ JPMorgan Nasdaq Equity Premium Income ETF 43.3B 
DFUS Dimensional U.S. Equity Market ETF 21.7B 
DFAS U.S. Small Cap Portfolio-ETF Class Shares 15.3B It ranks #38 of 594 in the industry
Based on market cap of $7B.
ABVX#35 Abivax ADR $8B PER - 
PRAX#36 Praxis Precision Medicines Inc $7B PER - 
AXSM#37 Axsome Therapeutics Inc $7B PER - IONS#38 Ionis Pharmaceuticals Inc $7B PER - 
IOVA#39 Iovance Biotherapeutics Inc $7B PER - 
FAQ
What kind of company is IONS?
IONS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IONS?
The market cap of IONS is approximately $7.3B, ranking 1,104 within its sector.
What is the 52-week high and low for IONS?
IONS has recorded a 52-week high of $86.74 and a low of $42.08.
